Close
Nordic 9Nordic 9

Biocodex (investor - Corporate Investor)

France biocodex.com
See something wrong or missing? Let us know

Biocodex is an independent multinational pharmaceutical company built on high- standards science and manufacturing

Average round investment:26.71M USD
Average number per year:1.3
Distribution: 2025 (2)2023 (1)2020 (1)
Portfolio companies: France Exeliom BiosciencesBelgium MRM HealthFrance MaaT Pharma
Mostly invests in: France France (3) Health services (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Biocodex

Name Criteria
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States KB Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France BOLD - Business Opportunities for L'Oréal Development
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Canada adMare BioInnovations
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Arab Emirates Oryx Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium UCB Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United States Obvious Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
United Kingdom 4BIO Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Belgium Quest for Growth
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
South Korea Korea Investment Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Top